1 Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target

Serdar Durdagi ORCID ID: 0000-0002-0426-0905 Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey

7 Abstract

2

3

4 5

6

8 Currently, the world suffers from a new coronavirus SARS-CoV-2 that causes COVID-19. 9 Therefore, there is a need for the urgent development of novel drugs and vaccines for COVID-10 19. Since it can take years to develop new drugs against this disease, here we used a hybrid 11 combined molecular modeling approach in virtual drug screening repurposing study to 12 identify new compounds against this disease. One of the important SARS-CoV-2 targets 13 namely type 2 transmembrane serine protease (TMPRSS2) was screened with NPC's NIH small 14 molecule library which includes approved drugs by FDA and compounds in clinical 15 investigation. We used 6654 small molecules in molecular docking and top-50 docking scored 16 compounds were initially used in short (10-ns) molecular dynamics (MD) simulations. Based 17 on average MM/GBSA binding free energy results, long (100-ns) MD simulations were 18 employed for the identified hits. Both binding energy results as well as crucial residues in 19 ligand binding were also compared with a positive control TMPRSS2 inhibitor, Camostat 20 mesylate. Based on these numerical calculations we proposed a compound (benzquercin) as 21 strong TMPRSS2 inhibitor. If these results can be validated by in vitro and in vivo studies, 22 benzquercin can be considered to be used as inhibitor of TMPRSS2 at the clinical studies.

23 Key Words: Drug repurposing, TMPRSS2, COVID19, SARS-CoV-2

24

25 *E-mail: <u>serdar.durdagi@med.bau.edu.tr</u>; durdagilab.com

26 **1. Introduction**

27 Coronaviruses (CoVs) belong to a single-stranded RNA (positive-sense) virus family which is 28 encapsulated by a membrane envelope. (Durdagi et al., 2020) There are four common types 29 of coronavirus (alpha, beta, gamma and, delta) and cause mild upper respiratory tract 30 diseases. (McKee et al., 2020) Human beta-coronaviruses are highly pathogenic. (Zhang et al., 31 2020) The SARS (Severe Acute Respiratory Syndrome)-CoV was appeared in Guangdong in 32 China and infected 8096 people worldwide in 2002-2003. The fatality rate was around 10% 33 (i.e., 774 deaths). In 2012, the MERS (Middle East Respiratory Syndrome)-CoV infected about 34 2500 people and the fatality rate was 36%. (Blanco-Melo et al., 2020) Currently, the world 35 suffers from a novel coronavirus SARS-CoV-2 that causes 2019 coronavirus disease (COVID-36 19). Like SARS and MERS-CoVs, SARS-CoV-2 mainly affects the lower respiratory tract. (Blanco-37 Melo et al., 2020) It is characterized by a number of symptoms such as fever, cough, diarrhea, 38 and general weakness. (Blanco-Melo et al., 2020) In more serious cases, it causes acute 39 respiratory distress syndrome and lung damage leading to inflammation and pneumonia. On 40 the 11th of March 2020, the WHO declared the COVID-19 as a pandemic. (Hoffmann et al., 41 2020) It affected the lives of hundreds of millions of people as a result of compulsory isolation 42 and quarantines in the world. (Sanders et al., 2020) SARS-CoV-2 targets host cells via Spike 43 protein that binds to the angiotensin-converting enzyme 2 (ACE2) receptor. The virus then 44 uses host cell receptors (i.e., type 2 transmembrane serine protease (TMPRSS2)) and 45 endosomes to enter the cells. TMPRSS2 facilitates cell entry of SARS-CoV-2 through the Spike 46 protein. After entering the host cell, viral proteins are synthesized that encode for the 47 replicase-transcriptase complex. (Mousavizadeh and Ghasemi 2020) Viral RNA was then 48 synthesized by RNA-dependent RNA polymerase. (Durdagi et al., 2020) The genome of SARS-49 CoV-2 encodes for different structural and non-structural proteins. (Sanders et al., 2020) The

important ones for drug development studies are Main Protease, and RNA-dependent RNA
 polymerase. (Cao et al., 2020) Currently these proteins are mainly targeted for drug screening
 and drug repurposing studies.

53 It is noteworthy that the method known as drug repurposing has become less costly in terms 54 of both time and resources. In our laboratory, the use of molecules in different indications has 55 been investigated with the studies we have done in this field in recent years. (Durdagi et al., 56 2018; Is et al., 2018; Tutumlu et al., 2020) Since the most of the preclinic and clinical studies 57 including pharmacokinetic and toxicological studies of approved or compounds in clinical 58 investigation phases have been already tested, they require less time to make them suitable 59 for new indications. The toxicity and ADME (absorption, distribution, metabolism and 60 excretion) studies which need long time to complete are not required as the molecules 61 considered in drug repositioning pass these stages already that should be applied before and 62 have well-defined profiles. Therefore, their use in epidemics is more suitable than new 63 molecules that have never been tested. Hence, in the current study we performed a virtual 64 drug repurposing study. The small molecules from NCGC-NIH Chemical Genomics Center 65 Pharmaceutical Collection (i.e., NPC library) were used in virtual screening studies at the active 66 site of developed TMPRSS2 model target protein.

67 **2. Materials and Methods**

68 We downloaded and prepared 7922 small compounds from NPC library 69 (https://tripod.nih.gov/npc/). Before the virtual screening, to remove non-specific 70 compounds, we performed some filtration criteria. Such as molecular weights of compounds 71 which are more than 1000 g/mol and smaller than 100 g/mol were removed from the library. 72 The compounds that have more than 100 rotatable bonds or hydrogen bond acceptor and 73 donor number that is higher than 10 were also removed. Thus, the total number of molecules

74 were decreased to 6654 before the docking simulations. These compounds were prepared 75 with LigPrep module (LigPrep, Schrodinger v.2017) of Maestro molecular modeling package. 76 Since the crystal structure of the TMPRSS2 was not available, we performed homology 77 modeling study. Swiss Model was used in homology modeling study (swissmodel.expasy.org). 78 The 5CE1 PBB coded serine protease hepsin was used as template structure. Sequence 79 identity between template and target proteins was 35.2%. Structural assessment studies on 80 the developed model have been performed. There was no any residue at the unfavorable 81 region at the Ramachandran's plot and protein reports showed no any steric clashes, bond 82 length or bond angle deviations at the structure, thus it was suitable to use as target protein 83 (Supplementary Materials, Figure S1). Before the docking, modeled target protein was 84 prepared using Protein Preparation module of Maestro molecular modeling package. In the 85 determination of protonation states of residues at the target protein, PROPKA was used. A 86 restrained optimization protocol was employed with OPLS3e force field for the target protein 87 model using 0.3 Å convergence criteria. Docking was implemented with Standard Precision 88 (SP) protocol of Glide using default settings. For the top-50 docking poses all-atom molecular 89 dynamics (MD) simulations were performed to mimic physiological conditions using 90 Desmond. Orthorhombic box was used with explicit water models (i.e., TIP3P) that have 10 Å 91 thickness from the edges of the protein. 0.15 M NaCl added to the simulation box to neutralize 92 the system. The particle mesh Ewald method was used for long range electrostatic 93 interactions. 9.0 Å cut-off was used for both electrostatic and van der Waals interactions. The 94 temperature (310 K) and pressure (1.01325 bar) throughout the simulations were kept 95 constant by Nose-Hoover thermostat (Evans and Holian, 1985) and Martyna-Tobias-Klein 96 barostat (Martyna et al., 1994) The OPLS3e force field was used in MD simulations. 1000 97 trajectory frames for each system during the simulations were collected. Molecular Mechanics Generalized Born Surface Area (MM/GBSA) method was then employed for these trajectories
and average MM/GBSA score for each studied compound was computed. The VSGB 2.0
solvation model in Prime module of Maestro was employed in MM/GBSA calculations.

101 **3.** Results and Discussion

102 Nowadays thanks to the effort of NIH Chemical Genomics Center, it is possible to obtain 103 electronic resources of collections of small molecules that have been registered. Combining 104 this with the power of recent advances of ligand- and target-driven based virtual screening 105 methods, it has been made easier to consider drug repurposing for any disease especially for 106 complex diseases. We used homology model target TMPRSS2 structure and screened the 107 prepared 6654 FDA approved drugs and compounds in clinical investigation phases from NPC 108 database using Glide/SP. Docking scores were between -8.445 and 3.438 kcal/mol. (Figure S2) 109 Due to the limited flexibility of both the target protein and the screened ligands in docking, 110 the identification of the compounds based on only docking scores in docking simulations can 111 lead to false-positive results. (Tutumlu et al., 2020) Moreover, although molecular docking 112 simulations may provide an insight into protein/screened ligand interactions, it is always 113 important to understand how these interactions are sustained throughout the performing MD 114 simulations. Thus, we used top-50 docking scored compounds and employed initially short 115 (10-ns) all-atom MD simulations in physiological and body temperature conditions. Docking 116 scores of top 50 compounds were between -8.445 and -6.962 kcal/mol. (see Figure 1 and Table 117 S1 at the Supplementary Materials). An in-house script was used to prepare simulation boxes 118 and analyze MD simulations. Desmond was used in all MD simulations. Tables S1 represents 119 the average MM/GBSA scores using the recorded 1000 frames (strided by 10 during the 120 simulations in each system) of the top-50 ligands. In order to compare the docking scores and 121 average MM/GBSA scores of identified hit compounds through our virtual screening protocol,

122 we also used same screening protocol for a well-known TMPRSS2 inhibitor, Camostat 123 mesylate. It is an approved small molecule compound for the treatment of pancreatitis in 124 Japan. It is found that Camostat mesylate prevents SARS-CoV-2 cell entry by inhibition of host 125 serine protease TMPRSS2. Its docking score was -5.444 kcal/mol at the binding pocket of the 126 TMPRSS2. Its corresponding average MM/GBSA score was calculated as -65.514 kcal/mol. 127 Figure S3 at the Supplementary Materials show 2D ligand interactions diagram of Camostat 128 mesylate at the binding site of SARS-CoV-2 TMPRSS2 target. Crucial residues were found as 129 Val280, Asp435, Ser436, Gln438, Gly439, Ser441, Ser460, and Val473. Based on average 130 MM/GBSA scores of short MD simulations, we selected 3 hits that have better scores than -131 70.0 kcal/mol, which are Benzquercin, Difebarbamate and N-benzoyl-l-tyrosyl-paba. Long 132 (100-ns) MD simulations were performed for these compounds and MM/GBSA scores were 133 re-calculated. Results showed that Benzquercin, N-benzoyl-l-tyrosyl-paba and Difebarbamate 134 have average MM/GBSA scores of -80.583, -56.162, and -66.567 kcal/mol, respectively. 135 Results showed that especially Benzquercin (a flavonoid) has maintained the interactions with 136 the binding pocket residues. Although average MM/GBSA score of Difebarbamate is slightly 137 decreased at the long MD simulations compared to short simulation, it has still similar range 138 of MM/GBSA score with positive control compound Camostat. Figure 2 represents the 2D and 139 3D ligand interactions diagram of Benzquercin at the binding site of TMPRSS2. The last frame 140 from 100-ns MD simulations was used. Crucial residues at the target were found as His296, 141 Glu299, Pro301, Leu302, Lys340, Lys342, Gly439, and Ser441 which share similar binding 142 pocket residues with positive control Camostat. Based on interaction fractions analysis Lys342 143 has the highest interaction fraction value with the hit compound throughout the 100-ns 144 simulations. The type of main interactions between the ligand and binding pocket residues 145 were hydrogen bonds through water bridges and hydrophobic interactions.

146 Interestingly, benzquercin was also found as potent hit compounds in our previous virtual 147 screening study using same protocol against another important cell-entry target of SARS-CoV-148 2 Spike/ACE2. (Durdagi et al, 2020). Its average score at the Spike/ACE2 interface was found 149 as -70.810 kcal/mol. Hence, these studies showed that benzquercin may also act as dual 150 inhibitor. It has been recognized that the treatment of "one target/one molecule" approach 151 of complex diseases is not so effective. The usage of combined drugs is not also appreciated 152 due to toxicity and/or undesirable drug-drug interactions. The recent and promising approach 153 to these complex diseases including COVID-19 is instead to develop/identify unique 154 compounds that act on multi-targets simultaneously which these targets are crucial in the 155 studied disease. Thus, based on in silico results, benzquercin has this potential.

156 4. Conclusions

157 Molecular modeling studies, such as virtual screening, reduce the time required to set new 158 targets for known drugs and also provide the advantage of being cost-effective. (Durdagi et 159 al, 2018 and 2020; Shoichet et al, 2002). In this study, a virtual drug repurposing study was 160 performed to identify new compounds against TMPRSS2 which is an important target for the 161 entry of the SARS-CoV-2 to the host cell. Thus, NPC small molecule library was screened 162 initially by docking simulations. Based on docking scores, top-50 compounds were used in 163 short MD simulations and their average binding free energies were calculated by MM/GBSA 164 method. Selected hits were used in longer MD simulations and results showed that especially 165 benzquercin maintains its interactions with the crucial residues throughout the simulations. If 166 these results can be validated by experimental studies, benzquercin can be considered to be 167 used as inhibitor of TMPRSS2 at the clinical studies.

168

170	Acknowledgment
171	This study was supported by Bahcesehir University, Bilimsel Araştırma Projeleri Birimi (BAP),
172	Project No: BAP.2020-01.01
173	
174	Conflict of Interest
175	The author declares that there is no any conflict of interest.
176	
177	References
178	Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K,
179	Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. (2020) Imbalanced
180	Host Response to SARS-CoV-2 Drives Development of COVID-19, Cell, 181(5):1036-1045.
181	
182	Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. (2020)
183	Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor
184	ACE2 in different populations. Cell Discovery 6:1-4.
185	
186	Durdagi S, Aksoydan B, Erol I, Kantarcioglu I, Ergun Y, Bulut G, Acar M, Avsar T, Liapakis G,
187	Karageorgos V, Salmas RE, Sergi B, Alkhatib S, Turan G, Yigit BF, Cantasir K, Kurt B, Kilic T.
188	(2018) Integration of Multi-scale Molecular Modeling Approaches with Experiments for the in
189	silico Guided Design and Discovery of Novel hERG-Neutral Antihypertensive Oxazalone and
190	Imidazolone Derivatives and Analysis of Their Potential Restrictive Effects on Cell Proliferation.
191	European Journal of Medicinal Chemistry, 145:273-290
192	

193	Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A, Birgul-Iyison N. (2020) Screening of
194	Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main
195	Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A
196	Virtual Drug Repurposing Study. ChemRxiv, DOI: 10.26434/chemrxiv.12032712.v2
197	
198	Evans DJ, Holian BL. The Nose–Hoover thermostat. (1985) The Journal of Chemical Physics.
199	83:4069-4074; DOI: 10.1063/1.449071
200	
201	Hoffmann M, Kleine-Weber H, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-
202	H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. (2020) SARS-CoV-2 Cell Entry Depends on
203	ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2):271-
204	280.
205	
206	Is YS, Durdagi S, Aksoydan B, Yurtsever M. (2018) Proposing Novel MAO-B Hit Inhibitors Using
207	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for
207 208	
	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for
208	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of their Therapeutic Activity and Toxic Effects. ACS Chemical Neuroscience 9(7),
208 209	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of their Therapeutic Activity and Toxic Effects. ACS Chemical Neuroscience 9(7),
208 209 210	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of their Therapeutic Activity and Toxic Effects. ACS Chemical Neuroscience 9(7), 1768-1782.
208 209 210 211	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of their Therapeutic Activity and Toxic Effects. ACS Chemical Neuroscience 9(7), 1768-1782. Martyna GJ, Tobias DJ, Klein ML. (1994) Constant pressure molecular dynamics algorithms.
 208 209 210 211 212 	Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of their Therapeutic Activity and Toxic Effects. ACS Chemical Neuroscience 9(7), 1768-1782. Martyna GJ, Tobias DJ, Klein ML. (1994) Constant pressure molecular dynamics algorithms.

216 Research, 157:104859. DOI:10.1016/j.phrs.2020.104859

218	Mousavizadeh L, Ghasemi S. (2020) Genotype and phenotype of COVID-19: Their roles in		
219	pathogenesis, Journal of Microbiology, Immunology and Infection, ISSN 1684-1182,		
220	https://doi.org/10.1016/j.jmii.2020.03.022.		
221			
222	Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. (2020) Pharmacologic Treatments for		
223	Coronavirus Disease 2019 (COVID-19): A Review [published online ahead of print, 2020 Apr		
224	13]. JAMA DOI: 10.1001/jama.2020.6019. DOI:10.1001/jama.2020.6019		
225			
226	Shoichet BK, McGovern, SL, Wei B, Irwin JJ (2002) Lead discovery using molecular docking.		
227	Current Opinion in Chemical Biology 6: 439-446.		
228			
229	Tutumlu G, Dogan B, Avsar T, Orhan MD, Calis S, Durdagi S. (2020) Integrating Ligand and		
230	Target-Driven Based Virtual Screening Approaches with in vitro human Cell Line Models to		
231	Identify Novel Hit Compounds Against BCL-2. Frontiers in Chemistry, DOI:		
232	10.3389/fchem.2020.00167		
233			
234	Zhang R, Wang X, Ni L, Di Xiao, Ma Baitao, Niu S, Liu C, Reiter RJ (2020). COVID-19: Melatonin		
235	as a potential adjuvant treatment. Life Sciences, 250:117583 DOI:		
236	https://doi.org/10.1016/j.lfs.2020.117583		
237			
238			
239			
240			

241 Figures





Figure 1. Docking scores of top-50 screened compounds from NPC database using Glide/SP.



249 **Figure 2.** (A) Surface representation of benzquercin at the binding pocket of TMPRSS2. The last frame from 100-ns MD simulations was used.

- (B) 3D ligand interactions diagram of benzquercin at the TMPRSS2 site. (C) Corresponding interactions were also depicted with 2D. (D) Interaction
- 251 fractions of binding pocket residues of TMPRSS2 with benzquercin throughout the MD simulations. Results show statistical results of collected
- 252 1000-trajectory frames throughout 100-ns MD simulations.

Supplementary Materials




Figure S1. Structural assessment of developed homology model structure of TMPRSS2. (A) Ramachandran's plot. While filled spheres show

each chiral residue at the target protein, filled triangles show Gly residues. (B) Local quality estimate of the derived model. (C) Normalized

QMEAN4 score and its comparison with similar size of a set of PDB structures.




Figure S2. Docking scores of all screened compounds at the binding pocket of TMPRSS2.




Figure S3. 2D ligand interactions diagram of Camostat at the binding pocket of TMPRSS2.

Compounds	Docking	Average
	Score	MM/GBSA
	(kcal/mol)	(kcal/mol)
Reproterol	-8.445	-47.283
Ociltide	-8.204	-57.549
Theodrenaline	-8.120	-26.242
Hexafluronium bromide	-8.045	-67.775
Cliropamine	-8.028	-38.601
Dab-452	-7.912	-60.818
Fenoterol	-7.839	-45.418
Frakefamide	-7.785	-42.928
mitoxantrone	-7.749	-44.749
Adimolol	-7.677	-58.356
Mesuprina	-7.649	-45.323
Esorubicin	-7.549	-42.773
Arbutamine	-7.515	-56.584
Penimepicycline	-7.499	-44.513
(Alpha.s)-alpha-[alpha-(2,4-dimethyl-9h-pyrido(2,3-	-7.463	-64.419
b)indol-9-yl)-p-tolyl]-n-((alpha.r)-		
alpha(hydroxymethyl)benzyl)cyclopentaneacetamide		
1,2,3-Dihydro-5-benzo(b)thienyl-2-(4-	-7.407	-44.191
phenylbutylamino)-1-propanol		
Quinidine	-7.380	-48.078
Tilisolol	-7.346	-24.419
Primozida	-7.341	-66.157
Ad 810	-7.340	-37.037
Carbuterol	-7.313	-18.889
Pronetalol	-7.293	-24.264
Vanyldisulfamide	-7.290	-61.900
Difebarbamate	-7.235	-76.184
Piroxicillin	-7.230	-57.173
Dapoxetine	-7.187	-49.660
Etanterol	-7.179	-12.707
Zinterol	-7.167	-42.080
Amosulalol	-7.145	-45.639
Fenprostalene	-7.136	-57.394
Carazolol	-7.128	-37.720
Benzquercin	-7.119	-96.802
Naftopidil	-7.113	-56.904
Denopamine	-7.107	-56.310
Brefonalol	-7.107	-44.698
Nardeterol	-7.106	-49.928

3-(Cis-2,6-dimethylpiperidino)-n-(4	-7.095	-52.087
methoxybenzoyl)sidnonimine		
Nordefrin	-7.083	-28.408
Ametantrone	-7.079	-49.325
Epicainide	-7.078	-60.527
Carteolol	-7.077	-29.853
Cinacalcet	-7.058	-52.311
N-benzoyl-l-tyrosyl-paba	-7.034	-71.183
Panamesine	-7.013	-56.305
Neraminol	-7.005	-45.562
Bucindolol	-7.003	-60.390
Unii-f6s9cmy4se	-7.002	-63.674
Giripladib	-6.975	-64.455
Pancopride	-6.969	-52.768
Nolinium bromide	-6.962	-51.067

Table S1. Docking scores of top-50 compounds at the TMPRSS2 binding site. These compounds were initially used in short (10-ns) MD simulations. Table also shows average MM/GBSA scores of these compounds from derived 1000-trajectories throughout the simulations.